Peter Zdziarski/LinkedIn
Feb 18, 2026, 15:24
Peter Zdziarski: How Glanzmann Thrombasthenia Suddenly Became ‘Mainstream’?
Peter Zdziarski, Vice President and Marketing Director at Glanzmann’s Research Foundation, shared a post on LinkedIn։
”Recently posted in the incredible Glanzmann Thrombasthenia Support Group (with almost 1 thousand patients, family members, and doctors!)
Just thinking out loud:
Has anyone else noticed how GT suddenly became ‘mainstream’?
And just as fast, a wave of unknown experts showed up out of nowhere?
I wish I knew why, but the point is this:
You are the expert in your GT. Your lived experience matters more than any trending take.
I know our community has been cautious about attention in the past. But let’s take advantage of the spotlight and turn it into new treatments and possibly even gene therapy!”
Stay updated with Hemostasis Today.
-
Jul 5, 2026, 11:16Grace Nyanudor: Coagulation Tests Start With Accurate Sample Handling Before Analysis
-
Jul 5, 2026, 11:05Muhammad Hamza: Why is Sodium Citrate the Anticoagulant of Choice for Coagulation Tests?
-
Jul 5, 2026, 10:53Lama Skieker: Severe Thrombocytopenia Demands Systematic Diagnosis Before Labeling ITP
-
Jul 5, 2026, 04:54Saneha Anjum Shaik: What Every Clinician Should Know Before Ordering Blood Tests
-
Jul 5, 2026, 04:37Mathis Richter: How The Bone Marrow Responds To Myocardial Infarction Predicts Clinical Outcome
-
Jul 5, 2026, 02:45Marie Luise Hütter-Krönke: Can a Short Course of BCMA-Targeted Therapy Induce Long-Term Remission in Refractory Autoimmune Disease?
-
Jul 5, 2026, 02:24Shreya Agarwa: Transforming Care For Adolescents With Heavy Menstrual Bleeding
-
Jul 4, 2026, 17:38Michael Stark: Greater Improvements in Cerebral Oxygenation With Restrictive Transfusion Thresholds
-
Jul 4, 2026, 17:27Reza Shojaei: How America Won the Plasma Race